In the largest M&A deal of 2020 so far, Gilead Sciences has agreed to pay US$21 B to acquire Immunomedics, a biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer. With the deal, Gilead gains access to Trodelvy™ (sacituzumab govitecan), which was the first anti-TROP-2 antibody-drug conjugate therapy to gain FDA approval in April 2020. Trodelvy will complement Gilead’s marketed CAR-T therapies Yescarta® (axicabtagene ciloleucel) and Tecartus™ (brexucabtagene autoleucel), as well as Phase III asset magrolimab, which was gained from the US$4.9 B Forty Seven buyout in March 2020.